Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
MindMed
company
About
MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.
- 11 - 50
Highlights
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $72M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- May 30, 2019
- Number Of Employee
- 11 - 50
- Operating Status
- Active
MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. It was founded in 2019 and headquartered in New York, United States.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$72M
MindMed has raised a total of
$72M
in funding over 2 rounds. Their latest funding was raised on
Dec 14, 2020 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 14, 2020 | Post-IPO Equity | $72M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
MindMed is funded by 1 investors.
CIBC
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
CIBC
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
